Advertisement

Topics

Brolucizumab compares well with Eylea in Phase III study

07:54 EDT 21 Jun 2017 | thePharmaLetter

Novartis has reported that RTH258 (brolucizumab) 6mg met the primary and key secondary endpoints in two…

Original Article: Brolucizumab compares well with Eylea in Phase III study

NEXT ARTICLE

More From BioPortfolio on "Brolucizumab compares well with Eylea in Phase III study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...